Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ulcerative colitis
Biotech
Odyssey, Sionna join band of biotechs braving the IPO waters
Odyssey and Sionna swelled the pack of startups that will provide a look at how receptive public investors could be to biotech listings in 2025.
Nick Paul Taylor
Jan 21, 2025 5:27am
Sanofi, Teva tout midstage win for TL1A antibody in Crohn’s, UC
Dec 17, 2024 10:30am
OSE's ulcerative colitis prospect improves symptoms in phase 2
Jul 24, 2024 8:23am
Lilly inks $3.2B Morphic buyout to take on Takeda in IBD
Jul 8, 2024 8:20am
Palisade's ulcerative colitis drug prevents symptoms in mice
May 23, 2024 4:30am
AltruBio raises $225M for midphase ulcerative colitis program
May 21, 2024 8:00am